NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Shares of Henry Schein split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were payable to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has initiated a stock buyback program on Thursday, December 13th 2018, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.1% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) announced its earnings results on Tuesday, May, 7th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.04. The business had revenue of $2.36 billion for the quarter, compared to analysts' expectations of $2.36 billion. Henry Schein had a return on equity of 18.35% and a net margin of 4.10%. The company's quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Henry Schein.

Henry Schein issued an update on its FY19 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of $3.38-3.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.42. Henry Schein also updated its FY 2019 guidance to $3.38-3.50 EPS.

16 analysts have issued twelve-month price targets for Henry Schein's shares. Their forecasts range from $62.00 to $96.00. On average, they anticipate Henry Schein's share price to reach $73.9993 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for Henry Schein.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 4 sell ratings, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Headlines about HSIC stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next few days.

Henry Schein saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 18,494,206 shares, an increase of 9.4% from the April 15th total of 16,899,233 shares. Based on an average daily trading volume, of 1,326,714 shares, the short-interest ratio is currently 13.9 days. Approximately 12.6% of the company's stock are short sold. View Henry Schein's Current Options Chain.

Some companies that are related to Henry Schein include Merck KGaA (MRK), Baxter International (BAX), Siemens Healthineers (SHL), Edwards Lifesciences (EW), Humana (HUM), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), FRESENIUS SE &/S (FSNUY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR INTL S/S (ESLOY), Align Technology (ALGN), McKesson (MCK) and Zimmer Biomet (ZBH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Citigroup (C), CVS Health (CVS), NVIDIA (NVDA), Honeywell International (HON), Amgen (AMGN), Activision Blizzard (ATVI) and Micron Technology (MU).

Henry Schein's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.62%), Select Equity Group L.P. (4.48%), FMR LLC (1.73%), JPMorgan Chase & Co. (1.62%), Geode Capital Management LLC (1.48%) and Northern Trust Corp (1.30%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Swedbank, State of Tennessee Treasury Department, Retirement Systems of Alabama, OppenheimerFunds Inc., TimesSquare Capital Management LLC and New York State Common Retirement Fund. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

HSIC stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Select Equity Group L.P., JPMorgan Chase & Co., First Trust Advisors LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Janus Henderson Group PLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $68.66.

Henry Schein has a market capitalization of $10.24 billion and generates $13.20 billion in revenue each year. The company earns $535.88 million in net income (profit) each year or $4.13 on an earnings per share basis. Henry Schein employs 18,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com/.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]